Applied Therapeutics Files 8-K

TL;DR

APLT filed an 8-K on 8/29/25 for a material definitive agreement.

AI Summary

Applied Therapeutics, Inc. filed an 8-K on August 29, 2025, reporting an entry into a material definitive agreement. The filing also includes other events and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located in New York.

Why It Matters

This 8-K filing indicates a significant event for Applied Therapeutics, Inc., potentially related to a new agreement that could impact its business operations and financial standing.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting a definitive agreement, with no immediate negative financial or operational news disclosed.

Key Numbers

• 001-38898 — Commission File Number (SEC File Number for Applied Therapeutics, Inc.)
• 81-3405262 — IRS Employer Identification No. (Tax identification for Applied Therapeutics, Inc.)

Key Players & Entities

• Applied Therapeutics, Inc. (company) — Registrant
• August 29, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• New York (location) — Principal Executive Offices City
• 212 220-9226 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 APLT The Nasdaq Stock Market LLC
• $75,000,000 — ng an aggregate offering price of up to $75,000,000 to or through the Agent. The offer and
• $49.3 m — ement for net proceeds of approximately $49.3 million, after deducting commissions and

Filing Documents

• aplt-20250829.htm (8-K) — 53KB
• aplt-ex5_1.htm (EX-5.1) — 17KB
• aplt-ex10_1.htm (EX-10.1) — 347KB
• 0000950170-25-112224.txt ( ) — 578KB
• aplt-20250829.xsd (EX-101.SCH) — 23KB
• aplt-20250829_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 29, 2025, Applied Therapeutics, Inc. (the "Company") entered into a Controlled Equity Offering SM Sales Agreement (the "Agreement") with Cantor Fitzgerald & Co. (the "Agent"), pursuant to which the Company may offer and sell, from time to time, shares (the "Shares") of its common stock, par value $0.0001 per share ("Common Stock"), having an aggregate offering price of up to $75,000,000 to or through the Agent. The offer and sale, if any, of the Shares will be made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-271887), which was filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") on May 12, 2023, and declared effective on May 19, 2023, as supplemented by the prospectus supplement (the "Prospectus Supplement") filed by the Company with the SEC on August 29, 2025. Sales of the Shares, if any, under the Agreement may be made in transactions that are deemed to be "at the market" offerings as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act"). The Company has no obligation to sell any of the Shares, and the Agent is not required to sell any specific number or dollar amount of the Shares. The Company and the Agent may at any time suspend or terminate the offering of Shares upon notice to the other party and subject to other conditions. Subject to the Company's request to sell Shares, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Stock Market, based upon the Company's instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company has provided the Agent with customary indemnification and contribution rights, and the Agent will be entitled to

01 Other Events

Item 8.01 Other Events. As previously disclosed, on August 11, 2023, the Company entered into the Sales Agreement (the "Leerink Partners Sales Agreement") with Leerink Partners LLC ("Leerink Partners"), pursuant to which the Company could offer and sell shares of Common Stock through Leerink Partners as sales agent, in sales deemed to be "at the market" offerings as defined in Rule 415(a)(4) promulgated under the Securities Act. Effective as of August 29, 2025, in connection with entry into the Agreement, the Company terminated the Leerink Partners Sales Agreement. Following the termination of the Leerink Partners Sales Agreement, the Company may not offer or sell any additional shares of Common Stock under the Leerink Partners Sales Agreement or the related prospectus, dated August 11, 2023. From August 11, 2023 to August 29, 2025, the Company sold 20,615,976 shares of Common Stock pursuant to the Leerink Partners Sales Agreement for net proceeds of approximately $49.3 million, after deducting commissions and offering expenses. The foregoing description of the Leerink Partners Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Leerink Partners Sales Agreement, a copy of which was filed as Exhibit 1.1 to the Company's Current Report on Form 8-K filed with the SEC on August 11, 2023, and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Document 5.1 Opinion of Goodwin Procter LLP 10.1 Controlled Equity Offering SM Sales Agreement, dated as of August 29, 2025, by and between Cantor Fitzgerald & Co. and Applied Therapeutics, Inc. 23.1 Consent of Goodwin Procter LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APPLIED THERAPEUTICS, INC. Date: August 29, 2025 By: /s/ Les Funtleyder Les Funtleyder, Interim Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR